Thermo-kinetic mixing for pharmaceutical applications
Compositions and methods for making a pharmaceutical dosage form include making a pharmaceutical composition that includes one or more active pharmaceutical ingredients (API) with one or more pharmaceutically acceptable excipients by thermokinetic compounding into a composite. Compositions and methods of preprocessing a composite comprising one or more APIs with one or more excipients include thermokinetic compounding, comprising thermokinetic processing the APIs with the excipients into a composite, wherein the composite can be further processed by conventional methods known in the art, such as hot melt extrusion, melt granulation, compression molding, tablet compression, capsule filling, film-coating, or injection molding.
1. The method of making a pharmaceutical composition comprising the steps of:
making a melt blended pharmaceutical composite comprising processing one or more active pharmaceutical ingredients (APIs) with one or more pharmaceutically acceptable excipients by thermokinetic compounding for less than 300 seconds, wherein the thermokinetic compounding of the one or more active pharmaceutical ingredients and the one or more pharmaceutically acceptable excipients forms a melt blended pharmaceutical composite; and
processing the melt blended pharmaceutical composite by hot melt extrusion, melt granulation, compression molding, tablet compression, capsule filling, film-coating, or injection molding to make the pharmaceutical composition.
2. The method of claim 1 , wherein the one or more pharmaceutically acceptable excipients are selected from the group consisting of lactose, glucose, starch, crystalline cellulose, simple syrup, glucose solution, starch solution, gelatin solution, carboxymethyl cellulose, methyl cellulose, dried starch, sodium alginate, powdered agar, calcium carmelose, a mixture of starch and lactose, sucrose, glycerin and starch, lactose, sucrose esters, cyclodextrins, cellulose derivatives, calcium carbonate, kaoline, silicic acid, bentonite, colloidal silicic acid, talc, phosphatidyl choline derivatives, butter, hydrogenated oil, a mixture of a quarternary ammonium base and sodium lauryl sulfate, dipalmitoyl phosphadityl choline, deoxycholic acid and salts, sodium fusidate, stearates, sorbitan esters, polyoxyethylene sorbitan fatty acid esters, sodium lauryl sulfate, oleic acid, lauric acid, vitamin E TPGS, glycolic acid, salts of glycolic acid, starch, crystalline cellulose, starch solution, carboxymethyl cellulose, shellac, methyl cellulose, polyvinyl pyrrolidone, dried starch, calcium carmelose, polyethylene glycol, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene alkyl ethers, poloxamers (polyethylene-polypropylene glycol block copolymers), polyoxyethylated glycolysed glycerides, polyethylene glycols, polyglycolyzed glycerides, polyvinyl alcohols, polyacrylates, polymethacrylates, polyvinylpyrrolidones, cellulose derivatives, biocompatible polymers selected from poly(lactides), poly(glycolides), poly(lactide-co-glycolides), poly(lactic acid)s, poly(glycolic acid)s, poly(lactic acid-co-glycolic acid)s and combinations thereof.
3. The method of claim 1 , wherein the one or more pharmaceutically acceptable excipients are selected from the group consisting of a pharmaceutically acceptable polymer, a thermolabile polymeric excipient, and a non-polymeric excipient.
4. The method of claim 1 , wherein the thermokinetic compounding is thermokinetic mixing until melt blended.
5. The method of claim 1 , wherein the thermokinetic compounding is thermokinetic mixing prior to agglomeration.
6. The method of claim 1 , wherein the composite is a homogenous, heterogenous, or heterogeneously homogenous composite.
7. The method of claim 1 , wherein one or more pharmaceutically acceptable excipients is a polymer having a high melt viscosity.
8. The method of claim 1 , wherein the composition is formulated for immediate release, delayed release, or modified release.
9. The method of claim 1 , wherein the one or more APIs has a particle size that is reduced to an average size of from 1000 μm to 1 μm.
10. The method of claim 1 , wherein the one or more APIs has a particle size that is reduced to an average size of from 100 μm to 1 μm.
11. The method of claim 1 , wherein the one or more APIs has a particle size that is reduced to an average size of from 10 μm to 1 μm.
12. The method of claim 1 , wherein the one or more APIs has an average particle size that is less than 1 μm.
13. The method of claim 1 , wherein the one or more APIs comprises a small organic molecule, a protein, a peptide, or a polynucleic acid.
14. The method of claim 1 , wherein the one or more APIs comprises a thermally labile or poorly water-soluble API.
15. The method of claim 1 , wherein the thermokinetic compounding is at an average temperature that is at or below a glass transition temperature or a melting point of the at least one API.
16. The method of claim 1 , wherein the composite comprises less than about 1.0% degradation products of the at least one API.
17. The method of claim 1 , wherein, after the thermokinetic compounding, the at least one API has at least about 94% drug potency as compared to the at least one API before the thermokinetic compounding.
18. The method of claim 1 , wherein the composite is a single phase, amorphous composite.
19. The method of claim 1 , wherein the composite is a single phase, miscible composite.